{"id":"imovax-polio-inactive-poliovirus-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2107962","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains chemically inactivated poliovirus types 1, 2, and 3, which cannot cause disease but trigger a humoral immune response. B cells recognize the viral antigens and produce neutralizing antibodies that protect against infection if the vaccinated person is exposed to wild-type poliovirus. This provides long-lasting immunity without the risk of vaccine-derived poliovirus that can occur with live attenuated vaccines.","oneSentence":"IMOVAX POLIO stimulates the immune system to produce antibodies against all three types of poliovirus by introducing inactivated (killed) virus particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:13.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3"}]},"trialDetails":[{"nctId":"NCT02005536","phase":"PHASE4","title":"Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-12","conditions":"Poliomyelitis, Polio","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SP059","IMOVAX POLIO®"],"phase":"marketed","status":"active","brandName":"IMOVAX POLIO®: Inactive Poliovirus Vaccine","genericName":"IMOVAX POLIO®: Inactive Poliovirus Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"IMOVAX POLIO stimulates the immune system to produce antibodies against all three types of poliovirus by introducing inactivated (killed) virus particles. Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}